{"id":862620,"date":"2025-06-23T09:41:54","date_gmt":"2025-06-23T13:41:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/"},"modified":"2025-06-23T09:41:54","modified_gmt":"2025-06-23T13:41:54","slug":"vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/","title":{"rendered":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial"},"content":{"rendered":"

<\/p>\n

\nVSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial<\/p>\n

SAN JOSE, Calif.–(BUSINESS WIRE<\/a>)–VSee Health, Inc.<\/a> (Nasdaq: VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation<\/a> based out of UCLA\u2014the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions.<\/p>\n

\nThe proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab marke<\/a>t<\/a>, where telehealth could disrupt traditional physical therapy with better adherence and lower costs. Success also paves the way for gamified telerehabilitation in other areas, e.g. multiple sclerosis, spinal cord injury, and traumatic brain injury rehab.<\/p>\n

\nProfessor of neurology at UCLA and a co-principal investigator, Dr. Steven Cramer, MD affirms, \u201cReaching Phase 3 in a clinical trial of this scale is a hard-won milestone that has been twelve years in the making\u2014one that wouldn\u2019t have been possible without the right partners. VSee Health\u2019s HIPAA-compliant platform has been instrumental in ensuring secure, seamless delivery of our interventions\u2014critical for maintaining compliance and engagement in a large-scale trial like this.\u201d<\/p>\n

\nDr. Milton Chen, PhD, Co-CEO of VSee Health adds, \u201cWe\u2019re grateful and proud of VSee\u2019s role in two of the only nationwide U.S. stroke tele-rehab trials. This Phase 3 trial validates telehealth as a scalable, cost-effective model for neurorehabilitation, and positions VSee as the go-to platform for the next wave of value-based virtual care that improves outcomes while reducing costs.\u201d<\/p>\n

\nThis trial further solidifies VSee\u2019s position as a key player in the telerehab market, building on VSee\u2019s prior role in Phase 1<\/a> and Phase 2<\/a> of this neurology study.<\/p>\n

\nEnrollment for the clinical trial begins Q3 2025, with the study combining independent and remote therapist-supervised games and exercises via VSee to overcome barriers like limited access to physical therapy clinics and poor patient motivation.<\/p>\n

Forward-Looking Statements<\/i><\/b><\/p>\n

This press release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cseeks,\u201d or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company\u2019s ability to regain compliance with Nasdaq\u2019s listing rules within the required timeframe. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Company\u2019s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-K and other SEC-filed documents. Such filing copies are available on the SEC\u2019s website <\/i>www.sec.gov<\/i><\/a>. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to rely on forward-looking statements.<\/i><\/p>\n

About VSee Health<\/b><\/p>\n

\nTrusted by top health systems and researchers, VSee Health provides a highly customizable and HIPAA-compliant digital health platform and services to effectively deliver integrated healthcare from a distance\u2014bridging gaps in access, engagement, and data security. Visit vsee.com<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250623877663\/en\/<\/a><\/span><\/p>\n

\nAnne Chang
\n
VSee Health
\n
media@vsee.com<\/a><\/p>\n

\nSteven C. Cramer, MD
\n
sccramer@mednet.ucla.edu<\/a><\/p>\n

\nInvestor Relations
\n
Dave Gentry
\n
RedChip Companies
\n
1-407-644-4256
\n
VSEE@redchip.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Neurology Software Telemedicine\/Virtual Medicine Physical Therapy Health Health Technology Technology Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial SAN JOSE, Calif.–(BUSINESS WIRE)–VSee Health, Inc. (Nasdaq: VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA\u2014the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions. The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market, where telehealth could … <\/p>\n

Continue reading “VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-862620","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial SAN JOSE, Calif.–(BUSINESS WIRE)–VSee Health, Inc. (Nasdaq: VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA\u2014the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions. The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market, where telehealth could … Continue reading "VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T13:41:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial\",\"datePublished\":\"2025-06-23T13:41:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/\"},\"wordCount\":652,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/\",\"name\":\"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-06-23T13:41:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk","og_description":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial SAN JOSE, Calif.–(BUSINESS WIRE)–VSee Health, Inc. (Nasdaq: VSEE) a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA\u2014the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions. The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market, where telehealth could … Continue reading \"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-23T13:41:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial","datePublished":"2025-06-23T13:41:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/"},"wordCount":652,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/","name":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-06-23T13:41:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250623877663r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vsee-powers-groundbreaking-nih-stroke-recovery-study-in-phase-3-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VSee Powers Groundbreaking NIH Stroke Recovery Study in Phase 3 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=862620"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862620\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=862620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=862620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=862620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}